Ashvattha Therapeutics is a clinical-stage biopharmaceutical company that develops precision nanomedicines for ophthalmology diseases.
Ashvattha Therapeutics has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in January 2025.
Ashvattha Therapeutics's investors include Tribe Capital, EcoR1 Capital, Plum Alley, Sam Altman, Modi Ventures.
Ashvattha Therapeutics is headquartered in Redwood City, United States.
Ashvattha Therapeutics is a clinical-stage biopharmaceutical company that develops precision nanomedicines for ophthalmology diseases.
Ashvattha Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ashvattha Therapeutics — Funding & Investors." VCBacked, January 13, 2025, https://www.vcbacked.co/company/ashvattha-therapeutics. Accessed July 31, 2026.
VCBacked. (2025). Ashvattha Therapeutics — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/ashvattha-therapeutics
{{cite web |title=Ashvattha Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ashvattha-therapeutics |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated